

injurious that he could through his administration have them removed immediately from the market. I believe, however, that he is taking a different course because of the complexities of these issues. He prepared for the Federal Register his judgments. If the companies would like to have hearings and other judicial procedures, I think this is quite appropriate. He is doing what he feels is best in relation to the importance of these issues.

I think he is doing it properly. He needs every bit of support to follow through with appropriate action.

Senator DOLE. And it may be that these hearings provide that support.

Dr. KUNIN. Yes.

Senator DOLE. It may be that we are, in effect, prejudging what should be done. I am not certain. But as a member of the committee I am interested in finding out.

Dr. KUNIN. That is the reason why we prepared the article for the New England Journal, because we wanted to demonstrate—to make the medical community aware of the fact that Dr. Ley was not working in a vacuum, that he was working in conjunction with a good opinion, so to speak. The reasons for these judgments should be explained to the physicians in detail.

I believe that this paper will be of great help to Dr. Ley in providing the climate of opinion that is so necessary for implementation of his actions.

Senator DOLE. I share your opinion, if there is such great unanimity, then I believe something should be done. I also agree that perhaps it is being done properly, and if there is any danger of great injury it can be, as I understand, speeded up by the FDA.

Dr. KUNIN. Oh, sure.

Senator DOLE. What I was really trying to determine was whether you feel that we should be prodding the FDA in this committee. If they are not moving quickly enough, and not responding to the findings made by your panel and other panels, then perhaps we should have had the FDA up here yesterday or last week or last year.

Dr. KUNIN. No, I think what you should do, if I may suggest, is to increase the budget for the Food and Drug Administration, increase the salary for the officers that have to take tremendous responsibility, and give them the staff that is necessary. If you compare the budget and the responsibility of the Food and Drug Administration to that of the National Aviation and Space Administration, there is a tremendous discrepancy. The Food and Drug Administration has been suffering for a long time under inadequate funding and inadequate status. I think this committee or the Congress should hasten to improve the status of the Food and Drug Administration, permit it to do some research, be able to attract first-rate individuals, and fill the vacant positions. There are plenty of vacancies there. There is no thanks for a man who is regulating an industry. There is no academic praise for a man who is regulating an industry. These people need a tremendous amount of support. They also have a great deal of discouragement. They need psychologic support. I think the committee would be very helpful in this area.

Senator DOLE. I share that view. I served on a House committee that delved into this to some extent, and found the very thing that you